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Abstract – A new cyclic nitrone spin trap, [4-(3’,3’-dibutyl-2’-oxy-3’H-isoindol-5’-
yloxy)butyl]triphenylphosphonium bromide  (MitoSpin), bearing a lipophilic cation has been 
prepared by a route that involves a novel Parham-type lithiation-cyclization of an isocyanate to give 
the isoindolinone core. MitoSpin accumulates in a membrane-potential dependent way in energized 
mitochondria and its oxidation could potentially be used in the study of oxidative stress resulting 
from reactive oxygen species generated in mitochondria. 
 
Introduction  
Mitochondria play a central role in energy metabolism and cell death, and consequently 
mitochondrial dysfunction contributes to many pathologies.1  It has been suggested that reduction of 
oxygen to superoxide by the mitochondrial respiratory chain ultimately leads to the production of 
highly reactive oxygen-centred radicals and carbon-centred radicals which are then responsible for 
many of these pathologies and for ageing on a cellular and whole organism level.2,3  Nitrones 1 
react with these highly reactive oxygen-centred and carbon-centred radicals (Y•) to give nitroxides 2 
that are more stable and longer lived (Scheme 1).4  The nitroxides 2 can be detected by EPR 
spectroscopy and the hyperfine splittings observed can often be used to identify the radical that led 
to their formation.  Thus, nitrones can be used as so-called spin traps for the study of radical 
processes in biological samples and there is interest in making spin traps that would accumulate 
within mitochondria and report on mitochondrial radical production.5-8  
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Scheme 1 Spin trapping with nitrones 
 Small molecules can be targeted to mitochondria by conjugation to lipophilic cations such 
as the alkyltriphenylphosphonium (TPP) cation.9,10  These lipophilic cations easily permeate 
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biological membranes due to their hydrophobicity and large ionic radius, and the large 
mitochondrial membrane potential (150 - 170 mV, negative inside) causes the several-hundred fold 
accumulation of these lipophilic cations into the mitochondrial matrix in accordance with the Nernst 
equation.9-11  This approach has been used to target antioxidants to mitochondria in cells, in vivo 
and in patients as a therapeutic approach10,12,13 and to drive the accumulation of probe molecules 
within mitochondria.14-16 Recently, three different spin traps have been targeted to mitochondria by 
conjugating them to TPP cations: α-phenyl-N-tert-butylnitrone (PBN),5 5-tert-butoxycarbonyl-5-
methyl-1-pyrroline N-oxide (BMPO)8 and 5-(diethoxyphosphoryl)-5-methyl-1-pyrroline N-oxide 
(DEPMPO)6,7 (Figure 1). The PBN derivative 3 produces long-lived nitroxide radicals with carbon-
centred radicals, but not with oxygen-centred radicals, while the targeted BMPO and DEPMPO 
spin traps 4 and 5 also react with oxygen-centred radicals to generate relatively stable spin adducts, 
which can be identified by their hyperfine couplings.  
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Figure 1 Mitochondria-targeted spin traps 
One problem with nitroxides is that they are rapidly converted into EPR-silent products in 
vivo through their reduction by ascorbate, glutathione and ubiquinol,17 and there is interest in 
developing spin traps that generate adducts that are resistant to such reduction.  1,1,3,3-
Tetraalkylisoindolin-2-yloxyl radicals18,19 are reduced more slowly than many,18 and we designed 
MitoSpin 6 as a spin trap that would be targeted to mitochondria by a TPP cation and was expected 
to generate sterically-protected (albeit less so than the tetralkyl derivatives) isoindolin-2-yloxyl 
radicals 7 by reaction with highly reactive oxygen-centred and carbon-centred radicals (Y•) 
(Scheme 2).  The nitrone moiety would be conjugated with an electron-donating alkoxy group to 
enhance reactivity with electron-deficient oxygen-centred radicals, and since the benzylic C-N bond 
of spin adducts 7 would be held in a ring perpendicular to the π system, this conjugation should not 
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encourage the fragmentation of the spin adducts.  The alkyl groups would serve the dual role of 
encouraging interaction with the mitochondrial inner membrane (the site of the main source of free 
radicals within mitochondria) and sterically protecting the radical centre in the adduct, while the 
presence of two tails rather than one should also discourage micelle formation.20 
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Scheme 2 Intended spin-trapping of radicals (Y•) by MitoSpin 6 
 
Results and Discussion 
 Fevig and co-workers had prepared a nitrone related to MitoSpin 6, via Lewis-acid mediated 
cyclization of an isocyanate to give an isoindolinone core.21  However,  in preliminary studies, we 
found a similar cyclization unsatisfactory, so MitoSpin 6 was prepared by first brominating 3-
methoxyphenylacetic acid 8 to give acid 9.  This was converted into ester 10 and two consecutive 
enolate alkylations produced ester 12 via ester 11.  Conversion to the free acid 13 could be achieved 
in base or by SN2 reaction with lithium iodide, and reaction with diphenylphosphoryl azide (DPPA) 
followed immediately by Curtius rearrangement of the acyl azide gave isocyanate 14.  Rather than 
hydrolyzing the isocyanate 14 to give an amine for transition metal-mediated carbonylation with 
carbon monoxide,22 we decided to investigate whether a Parham-type procedure23 involving lithium-
bromine exchange followed by intramolecular reaction between the resulting aryllithium and the 
isocyanate would give amide 15 directly.  Couture and co-workers had shown that isoindolinones 
could be made from carbamates in this way,24 and intermolecular reaction between phenyllithium 
and an isocyanate to produce an acyclic amide was known,25 but the intramolecular version of this 
reaction was new.  Therefore, we were delighted to find that the isocyanate 14 gave amide 15 in 
high yield when treated with tert-butyllithium.  Reduction to give amine 16 proceeded smoothly.  
Oxidation of amine 16 to nitrone 17 followed by deprotection to give phenol 19 was successful, but 
reversing the steps to give the phenol 18 first was more efficient.  Finally, coupling with 
commercially available phosphonium salt 20 gave MitoSpin 6, albeit in modest yield.  
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Scheme 3 Synthesis of MitoSpin 6 
To assess whether MitoSpin 6 accumulated within mitochondria driven by the membrane 
potential we used an ion-selective electrode that responds to the triphenylphosphonium (TPP) 
moiety (Figure 2). The electrode was inserted into a stirred, thermostated incubation chamber and 
showed the expected logarithmic response to five sequential additions each increasing the 
concentration of MitoSpin 6 by 1 µM to give a final concentration of 5 µM (Figure 2, arrowheads 
show additions). Isolated mitochondria were then added in the presence of the respiratory inhibitor 
rotenone to prevent generation of a membrane potential from endogenous substrates. This led to a 
slight decrease in the concentration of MitoSpin due to the expected adsorption of the compound to 
the mitochondrial surface.26,27  Addition of the respiratory substrate succinate to generate a 
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mitochondrial membrane potential led to a rapid decrease in the concentration of MitoSpin 6, 
consistent with its uptake into the mitochondrial matrix on induction of a membrane potential. To 
confirm that the uptake was due to the mitochondrial membrane potential, we next added the 
uncoupler carbonylcyanide p-(trifluoromethoxy)phenylhydrazone (FCCP) which abolished the 
mitochondrial membrane potential and led to a rapid efflux of MitoSpin 6 from the mitochondria. 
The electrode response to hydrophobic TPP compound is semi-quantitative due to electrode drift.26 
Even so, we can estimate that under these conditions the steady state concentration of MitoSpin 6 
outside energised mitochondria is approximately 3 µM and that the remainder of the is accumulated 
inside the mitcohndria.  From the incubation chamber volume and the intramitochondrial volume 
(~0.6 µL/mg protein28) this corresponds to approximately 3 mM concentration of MitoSpin 6 inside 
mitochondria, consistent with the ~1000-fold accumulation by the mitochondria expected from the 
Nernst equation for mitochondria with the expected mitochondrial membrane potential values of 
150 to 170 mV.9 Therefore, these data are consistent with uptake of MitoSpin 6 into mitochondria 
driven by the mitochondrial membrane potential, indicating that MitoSpin 6 behaves in a similar 
way to other hydrophobic TPP-conjugated compounds and that on addition to mitochondria it is 
rapidly taken up into the matrix.29  
 
 
Figure 2 Uptake of MitoSpin by energized mitochondria. An electrode sensitive to the TPP moiety 
of MitoSpin was inserted into 3 mL KCl buffer supplemented with 4 µg/mL rotenone with stirring 
at 37 °C and five consecutive 1 µM additions of MitoSpin were used to calibrate the response of the 
ion-selective electrode (arrowheads). The addition of rat liver mitochondria (mitos; 1 mg 
protein/mL), succinate (10 mM) and FCCP (1 µM) are indicated. This result is typical of three 
independent measurements. 
 
 Next MitoSpin 6 was assessed as a spin trap.  The Fenton reaction between iron(II) ions and 
hydrogen peroxide was used to generate hydroxyl radicals (Scheme 4) in the presence of MitoSpin 
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6, and the EPR spectrum obtained at a range of concentrations of each reactant was a narrow triplet 
(Figure 3).  The same spectrum was obtained when MitoSpin and hydrogen peroxide were 
irradiated with UV light.  The signal was very stable (72 h, without significant change), but could 
be abolished by treatment of the solution with glutathione or ascorbic acid.  This narrow triplet is 
not consistent with the hydroxy adduct 21 and is assigned as MitoSpinox 23 (Scheme 5), which has 
no β-hydrogen atom.  A related nitroxide, 5,5-dimethyl-2-pyrrolidone-1-oxyl (DMPOX), has a 
similar small hyperfine splitting of AN = 7.1 G for coupling with the nitrogen nucleus.30  Under the 
Fenton conditions it seems likely that the originally generated hydroxy adduct 21 is oxidized to the 
EPR-silent hydroxamic acid 22 (represented as the more thermodynamically stable tautomer31) by 
reaction with iron(III) ions.  A similar reaction has been reported for DMPO.32  Hydroxamic acid 22 
could also be formed by disproportionation of nitroxide 21 or by abstraction of a hydrogen atom 
from the nitroxide 21 by a second hydroxyl radical. Reaction between hydroxamic acid 22 and a 
hydroxyl radical would give MitoSpinox 23.  Reduction of MitoSpinox 23 with glutathione or 
ascorbic acid is not surprising as the electron-withdrawing carbonyl group means that the O-H bond 
dissociation energy of the hydroxamic acid 22 will be at least 20 kJ mol–1 higher than those of 
simple hydroxylamines.33  
Fe2      + H2O2 Fe3      + HO   + HO  
Scheme 4 
 
Figure 3 EPR spectrum of MitoSpinox 23, g = 2.0071, AN= 7.6 G, the bar indicates the scale for   
the magnetic field strength in Gauss. 
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Scheme 5  
 The high propensity of MitoSpin 6 to be oxidized means that it will not be useful for 
distinguishing between different radicals in mitochondria.  However, it is taken up by mitochondria 
and reacts with oxidizing agents to give a strong, simple EPR spectrum, so it may be useful for the 
detection of oxidative stress in mitochondria, when natural antioxidants are depleted.  Indeed, its 
oxidation products could also be quantified by other techniques such as HPLC-MS as markers of 
oxidative stress.  Furthermore, MitoSpin's ability to reduce oxidizing species, and its accumulation 
at the sites believed to be responsible for much of the endogenous oxidative stress in cells, gives it 
potential as a therapeutic antioxidant.34 
In conclusion, we have demonstrated a novel Parham-type cyclisation of an isocyanate to 
access an isoindolone skeleton, and used this as the key step in a concise synthesis of a new spin 
trap, MitoSpin 6.  MitoSpin 6 is a potentially useful mitochondria-targeted spin trap and could also 
be used therapeutically or as a probe to investigate mitochondrial oxidative stress in various models.  
 
Experimental 
Synthesis 
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Reactions under an inert atmosphere were carried out using oven-dried or flame-dried glassware. 
Solutions were added via syringe. THF was freshly distilled from sodium benzophenone. 
Dichloromethane was distilled from CaH2 prior to use. Reagents were obtained from commercial 
suppliers and used without further purification unless otherwise stated. 1H and 13C NMR spectra 
were obtained on a Bruker DPX/400 spectrometer operating at 400 and 100 MHz respectively. 1H 
NMR spectra in CDCl3 are referenced to residual chloroform at 7.26 ppm and in CD3OD are 
referenced to residual methanol at 3.31 ppm. 13C NMR spectra in CDCl3 are referenced to CDCl3 at 
77.16 ppm and in CD3OD are referenced to CD3OD at 49.00 ppm.  DEPT was used to assign the 
signals in the 13C NMR spectra as C, CH, CH2 or CH3. All coupling constants are measured in Hz. 
Mass spectra (MS) were recorded on a Jeol JMS700 (MStation) spectrometer.  Some IR spectra 
were obtained employing a Golden GateTM attachment that uses a type IIa diamond as a single 
reflection element so that the IR spectrum of the compound (solid or liquid) could be directly 
detected (thin layer) without any sample preparation. 
 
[4-(3’,3’-Dibutyl-2’-oxy-3’H-isoindol-5’-yloxy)butyl]triphenylphosphonium bromide  
(MitoSpin) 6.  A stirred solution of nitrone 19 (500 mg, 1.9 mmol), cesium carbonate (686 mg, 
2.10 mmol) and 4-bromobutyltriphenylphosphonium bromide (1.83 g, 3.83 mmol) in dry MeOH 
(15 mL) were heated to reflux for 48 h. The mixture was then partitioned between H2O and EtOAc, 
and the aqueous phase was extracted with EtOAc (2 x).  The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo to give a yellow solid foam. Recrystallization from EtOAc-
hexane gave MitoSpin 6 as an amorphous solid (298 mg, 24%). Mp: decomposes at 84 °C. δH 
(CDCl3, 400 MHz): 7.92-7.87 (6H, m), 7.80-7.77 (3H, m), 7.70-7.66 (7H, m), 7.22 (1H, d, J = 8.4 
Hz), 6.85 (1H, dd, J = 8.4, 2.0 Hz), 6.74 (1H, d, J = 2.0 Hz), 4.18 (2H, t, J = 5.8 Hz), 4.06-4.03 
(2H, m), 2.35-2.25 (2H, m), 2.13-2.05 (2H, m), 1.96-1.63 (4H, m), 1.24-1.13 (4H, m), 0.99-0.82 
(2H, m), 0.75 (6H, t J = 6.4 Hz), 0.61-0.48 (2H, m). δC (CDCl3, 100 MHz): 159.30 (C), 144.48 (C), 
135.10 (CH), 133.82 (d, J = 9.9 Hz, CH), 133.58 (CH), 130.55 (d, J =12.6 Hz, CH), 126.82 (C), 
120.89 (CH), 118.84 (d, J= 85.8 Hz, C) 114.24 (CH), 108.41 (CH), 84.18 (C), 67.19 (CH2), 37.21 
(CH2), 29.62 (d, J= 16.6 Hz, CH2), 24.83 (CH2), 22.51 (CH2), 22.05 (CH2), 19.52 (CH2), 13.90 
(CH3). IR (KBr, cm-1): 3051, 2929-2858, 1683, 1611, 1586, 1526.  LRMS (FAB/NOBA): 578 [M+ 
(phosphonium cation), 100]. HRMS: 578.3201. C38H45NO2P requires 578.3188.  
 
(2’-Bromo-5’-methoxyphenyl)acetic acid 9.  Bromine (8.3 mL, 162 mmol) was added dropwise to 
a solution of 3-methoxyphenylacetic acid 8 (25.7 g, 154 mmol) in CHCl3 (100 mL). The resulting 
mixture was allowed to stir overnight at rt and then poured into 20% aqueous sodium thiosulfate 
solution (300 mL). The layers were separated and the aqueous layer was extracted with CHCl3 (200 
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mL).  The combined organics were washed with 20% aqueous sodium thiosulfate solution, dried 
over MgSO4 and concentrated in vacuo to give the aryl bromide 7 as an off-white solid (37.9 g, 
100%); a small portion was recrystallized from EtOAc-hexane to give plates. Mp 108-109 °C. δH 
(CDCl3, 400 MHz): 7.46 (1H, d, J = 8.8 Hz), 6.85 (1H, d, J = 3.0 Hz), 6.74 (1H, dd, J = 8.8, 3.0 
Hz), 3.80 (2H, s), 3.78 (3H, s). δC (CDCl3, 100 MHz): 176.50 (C), 158.95 (C), 134.27 (C), 133.40 
(CH), 117.29 (CH), 115.46 (C), 114.84 (CH), 55.51 (CH3), 41.49 (CH2). IR (KBr cm-1): 2949-2856, 
1692, 1594, 1571. LRMS (EI+), m/z: 246 [M+• (81Br), 28%)], 244 [M+• (79Br), 28%)], 201 (20), 199 
(20), 165 (100). HMRS: 243.9734. C9H9BrO3 requires (M+•) 243.9735. 1H and 13C NMR matches 
literature.35 
 
Methyl 2-(2’-bromo-5’-methoxyphenyl)acetate  10.  Concentrated sulfuric acid (6 drops) was 
added to a solution of the carboxylic acid 9 (37.9 g, 155 mmol) in methanol (150 mL). The 
resulting mixture was stirred at rt overnight. The reaction was concentrated in vacuo to 
approximately 20 mL and the mixture taken up in EtOAc and washed with 1 M NaOH(aq), then with 
brine.  The organics were dried over MgSO4 and concentrated in vacuo to give ester 10 (37.6 g, 
98%) as a yellow oil, which crystallized on standing to give prisms. Mp: 38-40 °C (Lit.36 oil). δH 
(CDCl3, 400 MHz):  7.43 (1H, d, J = 8.8 Hz), 6.84 (1H, d, J = 3.0 Hz), 6.70 (1H, dd, J = 8.8, 3.0 
Hz), 3.77 (3H, s), 3.74 (2H, s), 3.71 (3H, s). δC (CDCl3, 100 MHz): 170.98 (C), 158.99 (C), 135.04 
(C), 133.38 (CH), 117.22 (CH), 115.44 (C), 114.64 (CH), 55.53 (CH3), 52.29, (CH3), 41.73 (CH2) 
IR (thin layer, cm-1) 3007, 2952, 1743.  LRMS (EI+), m/z: 260 [M+• (81Br), 16%], 258 [M+• (79Br), 
16], 179 (100). HMRS: 257.9892 and 259.9871.  C10H1179BrO3 requires (M+•) 257.9892, and 
C10H1181BrO3 requires (M+•) 259.9872. IR matches literature and 1H NMR spectrum is similar, but 
not the same as that recorded in a different solvent (CCl4).36 
 
Methyl 2-(2’-bromo-5’-methoxyphenyl)hexanoate 11.  n-BuLi (43 mL, 2.5M in hexane, 109 
mmol) was added dropwise to a stirred solution of diisopropylamine (15 mL, 109 mmol) in dry 
THF (150 mL) at –78 °C under argon ensuring that the internal temperature remained below –60 
°C. The resulting solution was allowed to stir for 15 min and a solution of methyl ester 10 (25 g, 99 
mmol) in dry THF (200 mL) was added dropwise ensuring that the internal temperature remained 
below –60 °C.  The reaction mixture was allowed to stir for 15 min and then butyl iodide (12.0 mL, 
109 mmol) was added dropwise.  The mixture was allowed to warm to rt and stirred overnight. The 
reaction was quenched by the addition of ice cold H2O and extracted with Et2O.  The organic layer 
was washed with H2O, dried over MgSO4, and concentrated in vacuo to give a brown oil. The oil 
was purified using flash chromatography on silica gel eluting with hexane followed by hexane-Et2O 
(3:2) to afford the ester 11 as a yellow oil (20.7 g, 91%). Rf [SiO2, hexane-Et2O (3:2)]: 0.63. δH 
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(CDCl3, 400 MHz): 7.43 (1H, d, J = 8.8 Hz), 6.93 (1H, d, J = 3.1 Hz), 6.67 (1 H, dd, J = 8.8, 3.1 
Hz), 4.09 (1H, t, J = 7.5 Hz), 3.77 (3H, s), 3.65 (3H, s), 2.07-1.98 (1H, m), 1.78-1.70 (1H, m), 1.36-
1.21 (4H, m), 0.82 (3H, t, J = 6.9 Hz). δC (CDCl3, 100 MHz):  174.04 (C), 159.21 (C), 139.87 (C), 
133.46 (CH), 115.28 (CH), 114.34 (C), 114.34 (CH), 55.50 (CH3), 52.13 (CH3) 49.99 (CH), 33.16 
(CH2), 29.62 (CH2), 22.58 (CH2), 13.98 (CH3). IR (thin layer, cm-1) 3010-2800, 1737, 1595, 1572.  
LRMS (EI+), m/z: 316 [M+• (81Br), 49%], 314 [M+• (79Br), 49%], 257 (12), 314 (12), 235 (100). 
HMRS: 314.0518 and 316.047.  C14H1979BrO3 requires (M+•) 314.0518, and C14H1981BrO3 requires 
(M+•) 316.0499. 
 
Methyl 2-(2’-bromo-5’-methoxyphenyl)-2-butylhexanoate 12.  n-BuLi (39 mL, 2.5 M in hexane, 
99 mmol) was added dropwise to a stirred solution of diisopropylamine (14 mL, 99 mmol) in dry 
THF (150 mL) at –78 °C under argon ensuring that the internal temperature remained below –60 
°C. The resulting solution was allowed to stir for 15 min and a solution of ester 11 (28.4 g, 90.1 
mmol) in dry THF (200 mL) was added dropwise ensuring that the internal temperature remained 
below –60 °C.  The reaction mixture was allowed to stir for 15 min and then butyl iodide (11 mL, 
99 mmol) was added dropwise.  The mixture was allowed to warm to rt and stirred overnight. The 
reaction was quenched by the addition of ice cold H2O and extracted with Et2O. The organic layer 
was washed with H2O, dried over MgSO4, and concentrated in vacuo to give a brown oil.  Flash 
chromatography on silica gel eluting with hexane followed by hexane-Et2O (3:2) afforded the ester 
12 as a yellow oil which crystallized on standing and was washed with hexane to give the ester as a 
an amorphous solid (22.9 g, 93%). Mp: 53-54 °C.  Rf [SiO2, hexane-Et2O (3:2)]: 0.65. δH (CDCl3, 
400 MHz):  7.45 (1H, d, J = 8.7 Hz), 6.91 (1H, d, J = 3.0 Hz), 6.65 (1H, dd, J = 8.7, 3.0 Hz), 3.81 
(3H, s), 3.67 (3H, s), 2.20-2.12 (2H, m), 1.99-1.92 (2H, m), 1.32-1.24 (4H, m), 1.11-1.05 (2H, m), 
0.96-0.90 (8H, m). δC (CDCl3, 100 MHz): 175.94 (C), 158.36 (C), 142.97 (C), 134.90 (CH), 116.87 
(CH), 114.33 (C), 111.94 (CH), 55.41 (CH3), 54.48 (C) 52.15 (CH3) 33.26 (CH2), 26.15 (CH2), 
23.11 (CH2), 14.01 (CH3). IR (thin layer, cm-1) 3010-2800, 1732, 1596. LRMS (EI+), m/z: 372 [M+• 
(81Br), 3%], 370 [M+• (79Br), 3], 291 (100). HRMS: 372.1125 and 370.1143.  C18H2781BrO3 requires 
(M+•) 372.1125 and C18H2779BrO3 requires (M+•) 370.1144. 
 
2-(2’-Bromo-5’-methoxyphenyl)-2-butylhexanoic acid 13.  5 M KOH(aq) (25 mL) was added to a 
stirred solution of ester 12 (10.0 g, 27.0 mmol) in DMSO (150 mL) and the resulting mixture heated 
to reflux overnight. The reaction was allowed to cool, was acidified with 5 M HCl(aq) and extracted 
with EtOAc (3 x).  The combined organic extracts were washed with brine, dried over MgSO4 and 
concentrated in vacuo to afford the carboxylic acid 13 as an off-white solid (8.08 g, 84%). A small 
portion was recrystallized from DCM to give needles. Mp: 163-165 °C.  δH (CDCl3, 400 MHz): 7.46 
 12 
(1H, d, J = 8.6 Hz, H-3’), 6.91 (1H, d, J = 3.0 Hz, H-6’), 6.66 (1H, dd, J = 8.6 Hz, 3.0 Hz, H-4’), 
3.80 (3H, s, CH3O), 2.24-2.16 (2H, m, CH2), 1.99-1.92  (2H, m, CH2), 1.33-1.11 (6H, m, 3x CH2), 
0.99-0.92 (2H, m, CH2), 0.88 (6H, t, J = 7.2 Hz, 2 x CH3). δC (CDCl3, 100 MHz): 181.71 (C), 
158.39 (C), 142.34 (C), 135.02 (CH), 116.99 (CH), 114.48 (C), 112.18 (CH), 55.46 (CH3), 54.54 
(C), 32.94 (CH2), 26.09 (CH2), 23.12 (CH2), 14.03 (CH3). IR (KBr, cm-1): 3010-2955, 2610, 1703, 
1597, 1570. LRMS (EI+), m/z: 358 [M+• (81Br), 2%], 370 [M+• (79Br), 2], 291 (M+• –•Br, 100), 85 
(35). HRMS: 356.0986 and 358.0977. C17H2579BrO3 requires (M+•) 356.0987 and C17H2581BrO3 
requires (M+•) 358.0969. 
 
1-Bromo-2-(5’-isocyanatonon-5’-yl)-4-methoxybenzene 14.  Triethylamine (9.2 mL, 66 mmol) 
was added to a stirred solution of carboxylic acid 13 (21.5 g, 60.2 mmol) in dry toluene (250 mL) at 
0 °C under argon. Diphenylphosphoryl azide (14.3 mL, 66 mmol) was then added and the resulting 
mixture allowed to stir for 15 min before heating to reflux for 18 h. The reaction was then quenched 
with saturated ammonium chloride solution and the mixture extracted with Et2O (3 x).  The 
combined organics were washed with brine, dried over MgSO4 and concentrated in vacuo to giva a 
brown oil.  Flash chromatography on silica gel eluting with hexane-EtOAc (4:1) gave the 
isocyanate 14 as an oil (20.8 g, 97%). Rf [SiO2, hexane-Et2O (4:1)]: 0.78 δH (CDCl3, 400 MHz): 
7.47 (1H, d, J = 8.8 Hz), 7.25 (1H, d, J = 2.8 Hz), 6.67 (1H, dd, J = 8.8, 2.8 Hz), 3.82 (3H, s), 2.74-
2.66 (2H, m), 1.90-1.83 (2H, m), 1.43-1.22 (6H, m), 1.00-0.84 (2H, m), 0.70 (6H, t, J = 7.6 Hz). δC 
(CDCl3, 100 MHz):  158.78 (C), 141.40 (C), 136.22 (CH), 121.87 (C), 117.41 (CH), 113.62 (CH), 
109.49 (C), 70.77 (C), 55.55 (CH3), 40.84 (CH2), 26.59 (CH2), 22.73 (CH2), 14.07 (CH3). IR (Thin 
layer, cm-1) 3010-2850, 2261, 1592, 1569.  MS, (EI+), m/z: 355 [M+• (81Br), 36%], 353 [M+• (79Br), 
36], 298 (100), 296 (100), 242 (60), 240 (61), 201 (39), 199 (36), 174 (81).  HMRS: 353.0991 and 
355.0968. C17H2479BrNO2 requires (M+•) 353.0990 and C17H2481BrNO2 requires (M+•) 355.0970. 
 
3,3-Dibutyl-2,3-dihydro-5-methoxyisoindol-1-one 15.  tBuLi (24 mL, 1 M in cyclohexane, titrated 
using 1,3-diphenyl acetone-p-tosylhydrazone, 24 mmol) was added dropwise to a stirred solution of 
the isocyanate 14 (4.00 g, 11.8 mmol) in dry THF (100 mL) at –78 °C under argon. The resulting 
mixture was allowed to warm to rt and stirred overnight before ice cold water was added.  The 
mixture was extracted with EtOAc and the organic layer was washed with brine, dried over MgSO4 
and concentrated in vacuo to afford amide 15 as an amorphous solid (3.02 g, 93%). Mp: 96-97 °C.  
δH, (CDCl3, 400 MHz): 7.71 (1H, d, J = 8.4 Hz), 6.93 (1H, dd, J = 8.4, 2.2 Hz), 6.87 (1H, s), 6.75 
(1H, d, J = 2.2 Hz), 3.87 (3H, s), 1.88-1.72 (4H, m), 1.24-1.14 (6H, m), 0.84-0.76 (8H, m). δC 
(CDCl3, 100 MHz): 170.56 (C), 163.16 (C), 153.23 (C), 125.17 (CH), 125.06 (C), 113.85 (CH), 
106.50 (CH), 64.80 (C), 55.75 (CH3), 39.24 (CH2), 25.62 (CH2), 22.90 (CH2), 14.01 (CH3). IR 
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(KBr, cm-1) 3286, 2955-2850, 1693, 1661, 1606, 1488.  LRMS (EI+), m/z: 275 (M+•, 1.5%), 218 
(100). HRMS: 275.1884. C17H25O2N requires (M+•) 275.1885. 
 
1,1-Dibutyl-2,3-dihydro-6-methoxy-1H-isoindole 16.  Borane-THF complex (51 mL of a 1 M 
solution in THF, 51 mmol) was added over 20 min to a stirred solution of amide 15 (3.50 g, 12.7 
mmol) in dry THF (50 mL) at 0 °C under argon and the mixture allowed to stir for 1 h. After this 
time the mixture was heated to reflux for 48 h. The reaction was then quenched by the slow addition 
of ice cold H2O (100 mL). 1 M NaOH(aq) was added and the mixture extracted with Et2O (2 x). The 
combined organic extracts were washed with brine (100 mL), dried over MgSO4 and then 
concentrated in vacuo to give an oil 16 (3.30 g, 99%). δH (CDCl3, 400 MHz): 7.16 (1H, d, J = 8.4 
Hz), 6.77 (1H, dd, J = 8.4, 2.4 Hz), 6.61 (1H, d, J = 2.4 Hz), 4.14 (2H, s), 3.82 (3H, s), 2.05-1.65 
(4H, m), 1.26-1.23 (6H, m), 1.10-1.04  (2H, m), 0.89 (6H, t, J = 7.2 Hz). The amine was dissolved 
in Et2O (20 mL) and ethereal HCl added affording the salt as a white precipitate. Mp: decomposed 
at 210 °C. δH (CDCl3, 100 MHz): 10.19 (2H, s), 7.17 (1H, d, J = 8.4 Hz), 6.88 (1H, dd, J = 8.4, 2.2 
Hz), 6.59 (1H, d, J = 2.2 Hz), 4.60 (2H, s), 3.82 (3H, s), 2.13-1.96 (4H, m), 1.57-1.48 (2H, m), 
1.42-1.23 (6H, m), 0.91 (6H, t, J = 7.2 Hz). δC (CDCl3, 100 MHz): 160.37 (C), 143.48 (C), 125.85 
(C), 124.00 (CH), 114.45 (CH), 108.28 (CH), 75.76 (C), 55.76 (CH3), 48.62 (CH2), 37.40 (CH2), 
25.73 (CH2), 22.82 (CH2), 14.05 (CH3). IR (KBr, cm-1): 3010-2800, 2717, 1621, 1588.  MS, (CI+), 
m/z: 262 [M+H+ (amine), 82%], 218 (24), 79 (100). HRMS: 262.2172. C17H28ON requires [M+H+ 
(amine)] 262.2171. 
 
1,1-Dibutyl-6-methoxy-1-H-isoindole-2-oxide 17. The hydrochloride salt of amine 16 (500 mg, 
1.68 mmol) was dissolved in MeOH (5 mL)  then NaOH (70.5 mg, 1.68 mmol),  Na2WO4 (58.0 mg, 
0.17 mmol) and  30% H2O2 in H2O (0.57 mL, 5.04 mmol) were added . The resulting mixture was 
then allowed to stir at room temperature under argon for 3 days. The reaction was then quenched 
with 20% Na2S2O3 in brine and extracted into EtOAc (3 x). The organic extracts were combined, 
dried over MgSO4 and concentrated to give an orange oil. Column chromatography, on silica gel, 
eluting with EtOAc-hexane (3:7) gave the nitrone 17 as a pale orange solid (157 mg, 34%). δH 
(CDCl3, 400 MHz): 7.67 (1H, s), 7.25 (1H, d, J = 8.4 Hz), 6.88 (1H, dd, J = 8.4, 1.6 Hz), 6.75 (1H, 
d, J = 1.6 Hz), 3.87 (3H, s), 2.14-2.07 (2H, m), 1.87-1.79 (2H, m), 1.30-1.11 (4H, m), 1.02-0.91 
(2H, m, CH2), 0.77 (6H, t, J = 7.2 Hz), 0.64-0.58 (2H, m). δC (CDCl3, 100 MHz): 160.09 (C), 
144.51 (C), 133.69 (C), 126.98 (C), 120.95 (CH), 113.01 (CH), 108.41 (CH), 84.23 (C), 55.75 
(CH3), 37.33 (CH2), 24.90 (CH2), 22.61 (CH2), 13.95 (CH3). IR (KBr, cm-1): 3100-2800, 1588, 
1525.  LRMS (EI+), m/z: 275 (M+•, 18%), 258 (82), 219 (100), 202 (41), 176 (96), 160 (32). HRMS: 
275.1887.  C17H25O2N requires (M+•) 275.1885. 
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3,3-Dibutyl-2,3-dihydro-1H-isoindol-5-ol 18.  BBr3 (54 mL of a 1 M solution in DCM, 54 mmol) 
was added dropwise to a solution of amine 16 (4.00 g, 15.3 mmol) in dry DCM (100 mL) at 0 °C 
under argon. The reaction mixture was then allowed to warm to rt for 72 h. After this time the 
reaction was quenched with ice-cold water.  The mixture was basified with 1 M NaOH(aq) and 
extracted with DCM (3 x). The combined organics were washed with brine, dried over MgSO4 and 
concentrated in vacuo to give phenol 18 as an amorphous solid (3.52 g, 93%). Mp: 110-111 °C.  δH 
(CD3OD, 400 MHz): 7.21 (1H, d, J = 8.3 Hz), 6.84 (1H, dd, J = 8.3, 2.2 Hz), 6.65 (1H, d, J = 2.2 
Hz), 4.46 (2H, s), 2.09-2.02 (2H, m), 1.93-1.85 (2H, m), 1.45-1.32 (6H, m), 1.26-1.16 (2H, m), 0.88 
(6H, t, J = 7.1 Hz). δC (CD3OD, 100 MHz): 159.74 (C), 143.85 (C), 125.14 (C), 125.04 (CH), 
117.61 (CH), 110.34 (CH), 76.59 (C), 49.65 (CH2), 37.42 (CH2), 26.53 (CH2), 23.79 (CH2), 14.17 
(CH3). IR (KBr, cm-1): 3433, 3310, 2955-2931, 2858, 1612, 1481, 1465. LRMS (CI+), m/z: 248 
[M+H+ (amine), 100%], 190 (25). HRMS: 248.2010. C16H26NO requires [M+H+ (amine)] 248.2015. 
 
3,3-Dibutyl-2-oxy-3H-isoindol-5-ol 19.  Sodium tungstate (1.00 g, 3.0 mmol) and hydrogen 
peroxide (2.1 mL, 90 mmol) were added to a stirred solution of amine 18 (1.50 g, 6.1 mmol) in dry 
methanol (20 mL) and the resulting mixture was stirred at rt for 72 h. The reaction mixture was then 
quenched with 20% aqueous sodium sulfite solution and extracted with DCM (3 x). The combined 
organic extracts were washed with brine, dried over MgSO4 and concentrated in vacuo to give an 
orange foam. The foam was triturated with EtOAc to give phenol 19 as an off-white solid (980 mg, 
61%). A small portion was recrystallized from hexane-EtOAc to give prisms. Mp: 193-195 °C. δH 
(CD3OD, 400 MHz): 8.12 (1H, s), 7.32 (1H, d, J = 8.4 Hz), 6.81 (1H, dd, J = 8.4, 2.0 Hz), 6.74 
(1H, d, J = 2.0 Hz), 2.14-2.01 (2H, m), 1.94-1.78 (2H, m), 1.23-1.06 (4H, m), 0.95-0.85 (2H, m), 
0.80 (6H, t, J= 6.4 Hz), 0.74-0.70 (2H, m, CH2).  δC (CD3OD, 100 MHz): 160.82 (C), 146.81 (C), 
139.29 (CH), 125.71 (C), 123.72 (CH), 116.73 (CH), 110.07 (CH), 85.11 (C), 37.69 (CH2), 25.88 
(CH2), 23.38 (CH2), 14.14 (CH3). IR (KBr, cm-1): 3439 (OH), 2954-2857, 1587, 1537.  LRMS (EI+), 
m/z: 261 (M+•, 10%), 244 (M+• – •OH, 23), 216 (M+• – H2O and HCN, 58), 205 (M+• – C4H8, 69%), 
188 (M+• – •OH and C4H8, 37), 162 (M+• –C4H8 and •Pr, 100), 146 (M+• – •Bu and BuH, 32). HRMS: 
261.1728. C16H23NO2 requires (M+•) 261.1729. 
 
EPR Spectroscopy. EPR spectra were acquired on a bench-top EPR machine with a permanent 
magnet and a magnetic sweep circuit (centre of field = 0.345 T, sweep width 25 mT) operating at a 
frequency of 9.8 GHz (X-band).  Acquisition parameters: RG 3.99 × 103, 2.76 mW, MA 0.5 G.  
Hyperfine couplings were derived from simulations and the g value calculated using strong pitch as 
the reference. 
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Reaction between MitoSpin 4 and hydroxy radicals in the presence of iron ions. Aqueous 
iron(II) sulfate (100 µL of a 1mM solution) and aqueous hydrogen peroxide (100 µL of a 1mM 
solution) were added to a solution of the MitoSpin 4 in DMF (100 µL of a 10 mM solution). The 
solution was then immediately transferred to a quartz flat cell and placed in the EPR spectrometer 
for analysis. 
 
Reaction between MitoSpin 4 and hydroxyl radicals generated by UV irradiation.  Aqueous 
hydrogen peroxide (150 µL of a 100 µM solution) was added to a solution of MitoSpin 4 in DMF 
(150 µL of a 30 mM solution) in a quartz cuvette and the solution irradiated with UV light (254 nm, 
12 W lamp) for 20 min before transferring to a quartz flat cell and placed in the EPR spectrometer 
for analysis.  
 
Mitochondrial Incubations.  Rat liver mitochondria were prepared by homogenization followed 
by differential centrifugation in 250 mM sucrose, 5 mM Tris-HCl, 1 mM EGTA, pH 7.4.37 Protein 
concentration was determined by the biuret assay using BSA as a standard.38 All incubations were at 
30 °C in KCl buffer (120 mM KCl, 1 mM EGTA, 10 mM HEPES, pH 7.2) supplemented with 10 
mM succinate and 4 µg/mL rotenone. A TPP-selective electrode was constructed and used as 
previously described39 to measure MitoSpin accumulation into rat liver mitochondria. 
 
Acknowledgements. We thank SPARC and the BBSRC for the purchase of the bench-top EPR 
spectrometer used.  The University of Glasgow for Caroline Quin's studentship.  The Wellcome 
Trust for funding Alison Hay.  Gates  Cambridge Trust for funding Jan Trnka. 
 
References  
1. (a) Wallace, D. C. Science 1999, 283, 1482-1488. (b) Lin, M. T.; Beal, M. F. Nature 2006, 
443, 787-795. 
2. Finkel, T. Nat. Rev. Mol. Cell Biol. 2005, 6, 971-976. 
3. Murphy, M. P. Biochem. J. 2009, 417, 1-13. 
4. Rosen, G. M; Britigan, B. E.; Halpern, H. J.; Pou, S. Free Radicals: Biology and Detection 
by Spin Trapping; OUP: Oxford, 1999. 
5. Murphy, M. P.; Echtay, K. S.; Blaikie, F. H.; Asin-Cayuela, J.; Cocheme, H. M.; Green, K.; 
Buckingham, J. A.; Taylor, E. R.; Hurrell, F.; Hughes, G.; Miwa, S.; Cooper, C. E.; Svistunenko, D. 
A.; Smith, R. A.; Brand, M. D. J. Biol. Chem. 2003, 278, 48534-48545. 
 16 
6. Hardy, M.; Chalier, F.; Ouari, O.; Finet, J. P.; Rockenbauer, A.; Kalyanaraman, B.; Tordo, 
P. Chem. Commun. 2007, 1083-1085. 
7. Hardy, M.; Rockenbauer, A.; Vasquez-Vivar, J.; Felix, C.; Lopez, M.; Srinivasan, S.; 
Avadhani, N.; Tordo, P.; Kalyanaraman, B. Chem. Res. Toxicol. 2007, 20, 1053-1060. 
8. Xu, Y.; Kalyanaraman, B. Free Radic. Res. 2007, 41, 1-7. 
9. Ross, M. F.; Kelso, G. F.; Blaikie, F. H.; James, A. M.; Cocheme, H. M.; Filipovska, A.; Da 
Ros, T.; Hurd, T. R.; Smith, R. A.; Murphy, M. P. Biochemistry (Mosc) 2005, 70, 222-230. 
10. Murphy, M. P.; Smith, R. A. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 629-656. 
11. Murphy, M. P.; Smith, R. A. J. Adv. Drug Deliv. Rev. 2000, 41, 235-250. 
12. Smith, R. A. J.; Porteous, C. M.; Coulter, C. V.; Murphy, M. P. Eur. J. Biochem. 1999, 263, 
709-716. 
13. Smith, R. A. J.; Porteous, C. M.; Gane, A. M.; Murphy, M. P. Proc. Natl. Acad. Sci.  U. S. 
A. 2003, 100, 5407-5412. 
14. Burns, R. J.; Smith, R. A. J.; Murphy, M. P. Arch. Biochem. Biophys. 1995, 322, 60-68. 
15. Lin, T. K.; Hughes, G.; Muratovska, A.; Blaikie, F. H.; Brookes, P. S.; Darley-Usmar, V.; 
Smith, R. A. J.; Murphy, M. P. J. Biol. Chem. 2002, 277, 17048-17056. 
16. Robinson, K. M.; Janes, M. S.; Pehar, M.; Monette, J. S.; Ross, M. F.; Hagen, T. M.; 
Murphy, M. P.; Beckman,  J. S. Proc. Natl. Acad. Sci.  U. S. A. 2006, 103, 15038-15043. 
17. Trnka, J.; Blaikie, F. H.; Smith, R. A. J.; Murphy, M. P. Free Radic. Biol. Med. 2008, 44, 
1406-1419. 
18. (a) Marx, L.; Chiarelli, R.; Guiberteau, T.; Rassat, A. J. Chem. Soc., Perkin 1 2000, 1181-
1182. (b) Marx, L.; Rassat, A. Angew. Chem. Int. Ed. 2000, 39, 4494-4496. (c) Reid, D. A.; Bottle, 
S. E.; Micallef, A. S. Chem. Commun. 1998, 1907-1908. 
19. The oxidation and reduction of this type of radical has been studied: Blinco, J. P.; Hodgson, 
J. L.; Morrow, B. J.; Walker, J. R.; Will, G. D.; Coote, M. L.; Bottle, S. E. J. Org. Chem. 2008, 73, 
6763-6771.  
20. (a) Cooper, A. Biophysical Chemistry; Royal Society of Chemistry: Cambridge, 2004, Ch. 
1. (b) Shearman, G. C.; Ces, O.; Templer, R. H.; Seddon, J. M. J. Phys.: Condens. Matter 2006, 18, 
S1105-S1124. 
21. Fevig, T. L.; Bowmen,  S. M.; Janowick, D. A.; Jones, B. K.; Munson, H. R.; Ohlweiler, D. 
F.; Thomas, C. E. J. Med. Chem. 1996, 39, 4988-4996. 
22. Orito, K.; Horibata, A.; Nakamura, T.; Ushito, H.; Nagasaki, H.; Yaguchi, M.; Yamashita, 
S.; Tokuda, M. J. Am. Chem. Soc. 2004, 126, 14342-14343. 
23. (a) Parham, W. E.; Bradsher, C. K. Acc. Chem. Res. 1982, 15, 300-305. (b) Clayden J. 
Organolithiums: Selectivity for Synthesis; Pergamon: London, 2002, Ch. 3. 
 17 
24. (a) Couture, A.; Deniau, E.; Lamblin, M.; Lorion, M.; Grandclaudon, P. Synthesis 2007, 
1434-1437.  (b) Lamblin, M.; Couture, A.; Deniau, E.; Grandclaudon, P. Org. Biomol. Chem. 2007, 
5, 1466-1471.  (c) Lamblin, M.; Couture, A,; Deniau, E.; Grandclaudon, P. Synthesis 2006, 1333-
1338. (d) Moreau, A.; Lorion, M.; Couture, A.; Deniau, E.; Grandclaudon, P. J. Org. Chem.  2006, 
71, 3303-3305.  (e) Moreau, A.; Couture, A.; Deniau, E.; Grandclaudon, P. Tetrahedron 2006, 62, 
5787-5790. 
25. Kuramochi, K.; Watanabe, H.; Kitahara, T. Synlett 2000, 397-399. 
26. Asin-Cayuela, J.; Manas, A. R.; James, A. M.; Smith, R. A.; Murphy, M. P. FEBS Lett. 
2004, 571, 9-16. 
27. Smith, R. A.; Kelso, G. F.; James, A. M.; Murphy, M. P. Methods Enzymol. 2004, 382, 45-
67. 
28. Ross, M. F.; Da Ros, T.; Blaikie, F. H.; Prime, T. A.; Porteous, C. M.; Severina, II; 
Skulachev, V. P.; Kjaergaard, H. G.; Smith, R. A.; Murphy, M. P. Biochem. J. 2006, 400, 199-208. 
29. Ross, M. F.; Prime, T. A.; Abakumova, I.; James, A. M.; Porteous, C. M.; Smith, R. A. J.; 
Murphy, M. P. Biochem. J. 2008, 411, 633-645. 
30. Rosen, G. M.; Rauckman,  E. J. Mol. Pharmacol. 1980, 17, 233-238. 26. Løvstad,  R. A. 
BioMetals 2003, 16, 435-439. 
31. Saldyka, M.; Mielke, Z. Vibrational Spectroscopy 2007, 45, 46-54. 
32. Makino, K.; Hagi, A.; Ide, H.; Murakami, A. Can. J. Chem. 1992, 70, 2818-2827. 
33. Luo, Y. -R. Handbook of Bond Dissociation Energies in Organic Compounds; CRC press: 
Boca Raton, 2003. 
34. Review of nitrones as therapeutics: Floyd, R. A.; Kopke, R. D.; Choi, C.-H.; Foster, S. B.; 
Doblas, S.; Towner, R. A. Free Radic. Biol. Med. 2008, 45, 1361-1374. 
35. Jeong, J. H.; Weinreb, S. M. Org. Lett. 2006, 8, 2309-2312. 
36. Ambros, R.; von Angerer, S.; Wiegrebe, W. Arch. Pharm. (Weinheim) 1988, 321, 481-486. 
37. Chappell, J. B.; Hansford, R. G. in Subcellular components:  preparation and fractionation; 
Birnie G. D., ed.; Butterworths: London, 1972, pp 77-91. 
38. Gornall A. G.; Bardawill, C. J.; David, M. M. J. Biol. Chem. 1949, 177, 751-766. 
39. Asin-Cayuela, J.; Manas A. R.; James, A. M.; Smith, R. A.; Murphy, M. P. FEBS Lett. 
2004, 571, 9-16 
 
 
 
